Vicky Tran’s Post

In the wake of last week's National Organ Day, a poignant inquiry surfaces regarding societal engagement—or the conspicuous absence thereof—in acknowledging not only this significant day but also other critical health awareness initiatives, such as Breast Cancer Awareness Month and Rare Disease Awareness. It beckons us to introspect on the societal disposition towards the dire scarcity of organs and the plight of countless individuals languishing in the interminable wait for the #giftoflife. This neglect raises profound ethical questions about our societal fabric's shift from altruism to a more egocentric ethos, prioritizing self-interest over communal welfare. Why does our collective conscience selectively navigate the myriad of health crises, amplifying some while inadvertently marginalizing others, such as the critical shortage of organ donors—a crisis claiming lives daily? This selective acknowledgment underscores a broader societal malaise, one characterized by a diminishing sense of communal responsibility and a burgeoning focus on individualism. It compels us to envisage the despair of those ensnared in the vicissitudes of organ shortage, their hopes for a new lease on life eclipsed by the grim reality of their situation. As we stand at this ethical crossroads, it is imperative to question when the tide of self-centeredness will ebb, paving the way for a resurgence of societal altruism. When will the pharmaceutical conglomerates and their executives transcend their avarice to champion organ donation advocacy genuinely? The exigency for a paradigm shift is palpable—a shift towards rekindling the flames of altruism, fostering a society where empathy and collective action illuminate the darkest recesses of human suffering. #organdonationawareness #SaveLivesGiveHope #DonateLife #BeAnOrganDonor #giftoflife AbbVie Pfizer Novartis Genentech Bristol Myers Squibb Astellas Pharma US Takeda Pharmaceuticals (formerly Nycomed) Merck United Therapeutics Corporation #socialcitenzship 

🔊🔊 this promises to be a really interesting webinar. #iPSC, #communitybuilding, #cellandgenetherapies, Cell and Gene Therapy Catapult

Thanks American Society of Gene & Cell Therapy for asking me to provide my "quick take" on consent for newly approved gene therapy treatments. Please also watch Samuel H. Hughes, MBA and Jean Johnston provide great guidance on consent for gene therapy trials! #genetherapy #informedconsent #approvedtherapies #patientcare #patientexperience

Are you looking to improve your understanding of the characteristics of a target product profile (TPP) and learn how to create a robust TPP to increase the likelihood of successful adoption of your #AdvancedTherapy? The Cell and Gene Therapy Catapult are hosting a webinar titled 'Developing a robust target product profile (TPP) for successful therapy adoption' on the 31st January where some of our key experts will be discussing our recently released TPP guide, the importance of a TPP and how to approach building one. Learn more: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #NonClinical

Check out three new, must-watch videos from ASGCT #PatientEducation! In Community Quick Takes: Informed Consent in Gene & Cell Therapy Research, we cover what an individual should know prior to giving their consent, and the role different stakeholders can play to improve this process. #genetherapy #celltherapy https://lnkd.in/e-hyyG5h

Let's connect at #ISCT2024! Join our panel discussion on current state and future directions of process analytical technologies. We're elevating your process with cell collections, cell expansion, and fill-finish. Looking forward to seeing you there. #CellandGeneTherapy #CGT ISCT, International Society for Cell & Gene Therapy

Only one week until our 'Overcoming Challenges in the Industrialisation of iPSC-derived therapies' webinar! Cell and Gene Therapy Catapult's Márcia F. Mata, will be discussing examples of how we are working to address key manufacturing challenges within the allogeneic cell therapy field; developing scalable, automated, and controlled processes to help bring these pioneering advanced therapies to patients will be discussed. Register now: https://buff.ly/3y9Z5XJ #iPSC #AdvancedTherapies #CellTherapies #GeneTherapies

Less than a week to go for #EUCROF24! CROs are telling us sponsor study protocols are becoming increasingly complex and sample-intensive. What we often hear: 🏨 More sites, more patients, and strict timelines... ..... Will the kits be customized for study needs? ..... Will sites have the kits in time for FPI? ..... Are the kits easy to use? What if the site makes collection errors? 🔍 More endpoints and specialized testing. It's hard to find the right labs... ..... Is there a lab near the site to process short-stability samples in<24h? ..... Can the lab develop and validate this biomarker assay on-time? ..... Can the lab do the testing according to protocol? ✈ Thousands of samples scattered across sites, labs, and with couriers... ..... Where is sample X? Is it collected? ..... Do I have sample visibility? How will I keep the sponsor informed? ..... Can I ensure sample & data integrity? 📊 Millions of data points generated - from disparate data sources... ..... When and how will data be transferred? What about ad hoc transfers? ..... Will I have a unified dataset in time for submission? ..... Is the data accurate, consistent and usable? Sounds familiar? Stop by our booth #4 if you're open to learning more about how we help CROs and sponsors generate endpoint data for their complex trials - while preventing delays and reducing costs. #clinicalresearch #clinicaltrials #clinicaloperations

A great panel discussing an important question. Looking forward to it!

📢 If you are attending Bioprocessing Summit this week, you'll want to visit Revvity at booth 415. We understand the complexities of bioprocessing. It requires precision and efficiency. Check out our latest innovations in this process or come by during Session B, board B38 to view our poster: Addressing the HEK293 Host Cell Protein Monitoring Challenges for Viral Vector Gene Therapy Manufacturing (presented by Christopher Ayres Naomi Musman Dan Cardillo and James Roet) 👏 #revvity #revvupresearch #BPIConf